Escherichia coli‐based cell‐free synthesis of virus‐like particles

@article{Bundy2008EscherichiaCC,
  title={Escherichia coli‐based cell‐free synthesis of virus‐like particles},
  author={Bradley C. Bundy and Marc J. Franciszkowicz and James R. Swartz},
  journal={Biotechnology and Bioengineering},
  year={2008},
  volume={100}
}
Virus‐like particles (VLP) have received considerable attention for vaccine, drug delivery, gene therapy and material science applications. Although the number of unique VLP and their applications are rapidly growing, the positive impact of VLP applications is limited by the current diverse, expensive, and typically low‐yielding production technologies available. These technologies, when scaled, often result in structurally and compositionally inconsistent products. We present Escherichia coli… 
Synthesis and Assembly of Hepatitis B Virus-Like Particles in a Pichia pastoris Cell-Free System
TLDR
A facile and rapid synthesis, assembly and purification methodology that could be applied as a rapid prototyping platform for vaccine development or synthetic biology applications and allows far greater throughput, which will expedite the screening of optimal assembly conditions for more robust and stable VLPs.
The incorporation of the A2 protein to produce novel Qβ virus‐like particles using cell‐free protein synthesis
TLDR
The co‐expression of the cytotoxic A2 protein and the coat protein of the bacteriophage Qβ is demonstrated to form a nearly monodispersed population of novel VLPs.
Bioengineering virus‐like particles as vaccines
TLDR
This review highlights historical and emerging VLP vaccine approaches that seek to specifically engineer a desirable immune response through modular VLP design, and those that seeks to improve bioprocess efficiency through inhibition of intracellular assembly to allow optimal use of existing purification technologies prior to cell‐free VLP assembly.
A rational approach to improving titer in Escherichia coli‐based cell‐free protein synthesis reactions
TLDR
This work proposes a process development strategy for Escherichia coli lysate‐based CFPS reactions that can be completed in as little as 48 hr, and observed the most dramatic increases in titer were due to the E. coli strain for the cell extract.
Escherichia coli-Based Cell-Free Protein Synthesis for Iterative Design of Tandem-Core Virus-Like Particles
TLDR
Modifications to the arginine-rich region typically found in wild-type HBcAg, the peptide linkers around the influenza antigen inserts, and the plasmid vector backbone to improve titer and quality were tested and demonstrated the potential for CFPS as a screening platform for VLPs.
Escherichia coli‐based cell free production of flagellin and ordered flagellin display on virus‐like particles
TLDR
This article describes Escherichia coli‐based cell‐free protein synthesis (CFPS) as a method to rapidly produce soluble phase 1 flagellin (FliC) protein from Salmonella typhimurium using a human Toll‐Like Receptor 5 (hTLR5)‐specific bioactivity analysis of purified flageLLin.
...
...

References

SHOWING 1-10 OF 44 REFERENCES
Cell-free synthesis and affinity isolation of proteins on a nanomole scale.
TLDR
The results show that standard low-cost, cell-free systems can serve for rapid preparation of purified proteins in amounts that can satisfy a number of needs of a research laboratory.
RNA Bacteriophage Capsid-Mediated Drug Delivery and Epitope Presentation
TLDR
Using knowledge of the three-dimensional structure and self-assembly mechanism of RNA bacteriophage capsids to develop novel virus-like particles (VLPs) for drug delivery and epitope presentation has potential for therapeutic and prophylactic intervention in disease.
Mimicking the Escherichia coli cytoplasmic environment activates long‐lived and efficient cell‐free protein synthesis
TLDR
By more closely replicating the physiological conditions of the cytoplasm of Escherichia coli, the Cytomim system provides a stable energy supply for protein expression without phosphate accumulation, pH change, exogenous enzyme addition, or the need for expensive high‐energy phosphate compounds.
Multiple presentation of foreign peptides on the surface of an RNA-free spherical bacteriophage capsid.
TLDR
The antigenicity of one such construct in vivo in mice is tested and it is shown that these particles are immunogenic and that antibody titres against the inserted peptide epitope can be obtained.
An Economical Method for Cell‐Free Protein Synthesis using Glucose and Nucleoside Monophosphates
TLDR
A cell‐free protein synthesis system with comparable protein yields that removes the most expensive substrates and lowers the cell‐ free reagent cost by over 75% (excluding extract, polymerase, and plasmid) while maintaining high energy levels is presented.
Efficient and scalable method for scaling up cell free protein synthesis in batch mode.
TLDR
A novel method for general cell free system scale-up in batch mode was applied to expression of E. coli chloramphenicol acetyl transferase and a GMCSF-scFv fusion protein and suggests that these surfaces provide significant benefit for protein expression and folding.
Rapid Expression and Purification of 100 nmol Quantities of Active Protein Using Cell‐Free Protein Synthesis
TLDR
To the authors' knowledge, this is the largest amount of actively expressed protein to be reported in a simple, fed‐batch cell‐free protein synthesis reaction.
Hepatitis core antigen produced in Escherichia coli: subunit composition, conformational analysis, and in vitro capsid assembly.
The production and biochemical and physiocochemical analysis are described of recombinant-produced hepatitis B virus core antigen (HBcAg capsid) and the corresponding particle produced by a deletion
...
...